Andy Extance charts how research into revolutionary targeted protein degradation therapies is moving from serendipity to ...

Things often seem either black or white within the targeted protein degradation (TPD) space. The biology behind degrading therapeutic targets that are difficult or dangerous to inhibit is well ...

In a study published today in the Journal of Clinical Investigation, Fred Hutch Cancer Center cancer chemical biologist ...

The degradation process, called deadenylation, occurs when RNA-binding proteins recruit the CCR4 ... By revealing the 3D ...

Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like ...

Learn about Nurix Therapeutics (NRIX) focusing on protein degradation in cancer treatment, with promising early-stage data ...

Protein levels that cause diseases can ... We will use neddylation, proteasome, and lysosomal system inhibitors to study degradation mechanisms. Identifying an E3 ligase capable of degrading ...

Barclays analyst Peter Lawson maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) today and set a price target of $31.00.